Targeting Key Mechanisms of Nutraceuticals in Chronic Pain: A Narrative Review
5 affiliations
- 1Department of Surgery, Dentistry, Paediatrics and Gynaecology, Section of Anesthesia, Intensive Care and Pain Therapy, Verona University Hospital, 37134 Verona, Italy
- 2Pain Therapy Centre, Palagi Hospital, 50122 Firenze, Italy
- 3Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy
- 4VIBRA Research Group, Paolo Procacci Foundation, 00193 Rome, Italy
- 5Department of Engineering for the Innovation Medicine, University of Verona, 37134 Verona, Italy
Abstract
Chronic pain (CP) is a major cause of disability worldwide and reflects interactions among multiple pathophysiological mechanisms. Despite the availability of pharmacological therapies, many patients continue to experience inadequate pain control, supporting interest in complementary approaches. Nutraceuticals have been investigated as potential adjuncts because several compounds modulate biological pathways implicated in pain persistence. This narrative review provides a mechanism-based overview of nutraceuticals in CP across five interconnected domains: neuroinflammation, oxidative stress and mitochondrial dysfunction, central sensitization, peripheral sensitization, and descending inhibitory modulation. Literature was identified in PubMed/MEDLINE and the Cochrane Library, with the final update completed on 8 October 2026; preclinical mechanisms and clinical efficacy were evaluated separately. Earlier short-term trials of alpha-lipoic acid suggested symptomatic improvement in diabetic peripheral neuropathy, whereas a 2024 Cochrane review found little or no benefit after six months. Evidence syntheses suggest possible analgesic effects of palmitoylethanolamide in mixed chronic pain populations and of curcuminoids in knee osteoarthritis. Clinical studies of omega-3 fatty acids also suggest a possible reduction in pain intensity, although substantial heterogeneity across conditions, formulations, and study designs limits interpretation. Across compounds, mechanistic plausibility generally exceeds evidence of clinical efficacy and direct target engagement in humans. Future studies should prioritize standardized formulations, clinically relevant outcomes, adequate follow-up, safety assessment, and mechanistic biomarkers within phenotype-informed pain management.
Related
- Nutraceuticals and Metabolic Health: Can Supplements Prevent Metabolic Syndrome? A Narrative Review
- Plant-derived bioactives and nutraceuticals in chronic prostatitis/chronic pelvic pain syndrome: clinical evidence, pain-sensitization mechanisms and nutritional translation
- MMP-7 as a non-invasive biomarker in interstitial lung diseases and other chronic respiratory diseases: a narrative review
- Ultra-Processed Foods in Early Life: Biological Mechanisms, Developmental Programming and Childhood Obesity—A Narrative Review
- The Proposed Vitamin D–Homocysteine Relationship in Cardiometabolic Health: A Narrative Review of Mechanisms, Evidence, and Research Phenotypes
BibTeX
@article{schweiger2026targeting,
title = {{Targeting Key Mechanisms of Nutraceuticals in Chronic Pain: A Narrative Review}},
author = {Vittorio Schweiger and Barbara Ganz and Erica Secchettin and Marta Nizzero and Luca Polati and Alessandro Picelli and Giustino Varrassi and Luca Dalle Carbonare and Leonardo Gottin and Alvise Martini and Enrico Polati},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18213488},
url = {https://www.mdpi.com/2072-6643/18/21/3488},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting Key Mechanisms of Nutraceuticals in Chronic Pain: A Narrative Review
AU - Vittorio Schweiger
AU - Barbara Ganz
AU - Erica Secchettin
AU - Marta Nizzero
AU - Luca Polati
AU - Alessandro Picelli
AU - Giustino Varrassi
AU - Luca Dalle Carbonare
AU - Leonardo Gottin
AU - Alvise Martini
AU - Enrico Polati
PY - 2026
DA - 2026/10/23
JO - Nutrients
DO - 10.3390/nu18213488
UR - https://www.mdpi.com/2072-6643/18/21/3488
AB - Chronic pain (CP) is a major cause of disability worldwide and reflects interactions among multiple pathophysiological mechanisms. Despite the availability of pharmacological therapies, many patients continue to experience inadequate pain control, supporting interest in complementary approaches. Nutraceuticals have been investigated as potential adjuncts because several compounds modulate biological pathways implicated in pain persistence. This narrative review provides a mechanism-based overview of nutraceuticals in CP across five interconnected domains: neuroinflammation, oxidative stress and mitochondrial dysfunction, central sensitization, peripheral sensitization, and descending inhibitory modulation. Literature was identified in PubMed/MEDLINE and the Cochrane Library, with the final update completed on 8 October 2026; preclinical mechanisms and clinical efficacy were evaluated separately. Earlier short-term trials of alpha-lipoic acid suggested symptomatic improvement in diabetic peripheral neuropathy, whereas a 2024 Cochrane review found little or no benefit after six months. Evidence syntheses suggest possible analgesic effects of palmitoylethanolamide in mixed chronic pain populations and of curcuminoids in knee osteoarthritis. Clinical studies of omega-3 fatty acids also suggest a possible reduction in pain intensity, although substantial heterogeneity across conditions, formulations, and study designs limits interpretation. Across compounds, mechanistic plausibility generally exceeds evidence of clinical efficacy and direct target engagement in humans. Future studies should prioritize standardized formulations, clinically relevant outcomes, adequate follow-up, safety assessment, and mechanistic biomarkers within phenotype-informed pain management.
SN - 2072-6643
ER -